Table 1.
Study population demographics (n = 77) and comparison between FGFR GA and WT patients.
| Variable | Modality | Metastatic | Mt/Fus (n = 26) | WT (n = 51) | p-Value |
|---|---|---|---|---|---|
| Age | Median (IQR) | 69 (62–76) | 69 (63–77) | 69 (61–75) | 0.45 |
| Sex | Male | 55 (71.4%) | 17 (65.4%) | 38 (74.5%) | 0.57 |
| Female | 22 (28.6%) | 9 (34.6%) | 13 (25.5%) | ||
| ECOG PS | 0 | 26 (33.8%) | 9 (34.6%) | 17 (33.3%) | 0.15 |
| 1 | 25 (32.4%) | 14 (53.8%) | 11 (21.6%) | ||
| 2 | 2 (2.6%) | 0 (0%) | 2 (3.9%) | ||
| Not available | 24 (31.2%) | 3 (11.5%) | 21 (41.2%) | ||
| Smoking | Never smoked | 16 (25.4%) | 7 (26.9%) | 9 (17.6%) | 0.55 |
| Current smoker | 9 (14.3%) | 3 (11.5%) | 6 (11.8%) | ||
| Former smoker | 38 (60.3%) | 11 (42.3%) | 27 (52.9%) | ||
| Not available | 14 (18.2%) | 5 (19.2%) | 9 (17.6%) | ||
| Tumor location | Bladder | 62 (80.5%) | 17 (65.4%) | 45 (88.2%) | 0.037 |
| Nonbladder | 15 (19.5%) | 9 (34.6%) | 6 (11.8%) | ||
| Surgery | No | 4 (5.2%) | 1 (3.8%) | 3 (5.9%) | 1 |
| Yes | 73 (94.8%) | 25 (96.2%) | 48 (94.1%) | ||
| Surgery extension | Cystectomy (RC) | 38 (49.3%) | 7 (28.0%) | 31 (64.6%) | 0.0076 |
| Nephroureterectomy/nephrectomy(NU) | 12 (15.6%) | 8 (32.0%) | 4 (8.3%) | ||
| NU + RC | 3 (3.9%) | 1 (4.0%) | 2 (4.2%) | ||
| TURBT | 20 (26%) | 9 (36.0%) | 11 (22.9%) | ||
| Lymphadenectomy | No | 36 (46.8%) | 15 (57.7%) | 21 (41.2%) | 0.37 |
| Yes | 38 (49.3%) | 11 (42.3%) | 27 (52.9%) | ||
| Not available | 3 (3.9%) | 0 (0.0%) | 3 (5.9%) | ||
| Bladder preservation | Radiotherapy | 4 (5.2%) | 2 (7.7%) | 2 (3.9%) | 0.86 |
| Chemo-radiotherapy | 6 (7.8%) | 2 (7.7%) | 4 (7.8%) | ||
| No | 67 (87.0%) | 22 (84.6%) | 45 (88.2%) | ||
| pT | 1 | 7 (9.1%) | 3 (11.5%) | 4 (7.8%) | 0.022 |
| 2 | 28 (36.4%) | 8 (30.8%) | 20 (39.2%) | ||
| 3 | 28 (36.4%) | 6 (23.1%) | 22 (43.1%) | ||
| 4 | 13 (16.8%) | 9 (34.6%) | 4 (7.8%) | ||
| Not available | 1 (1.3%) | 0 (0.0%) | 1 (2.0%) | ||
| pN | 0 | 14 (36.8%) | 3 (27.3%) | 11 (40.7%) | 0.81 |
| 1 | 11 (28.9%) | 4 (36.4%) | 7 (25.9%) | ||
| 2 | 12 (31.6%) | 4 (36.4%) | 8 (29.6%) | ||
| 3 | 1 (2.6%) | 0 (0%) | 1 (3.7%) | ||
| Grade | 2 | 2 (2.6%) | 1 (3.8%) | 1 (2%) | 1 |
| 3 | 73 (94.8%) | 25 (96.2%) | 48 (94.1%) | ||
| NA, n (%) | 2 (2.6%) | 0 (0.0%) | 2 (3.9%) | ||
| Variant histologies | Transitional cells | 70 (90.9%) | 23 (88.5%) | 47 (92.2%) | 0.71 |
| Squamous | 5 (6.5%) | 2 (7.7%) | 3 (5.9%) | ||
| Anaplastic | 1 (1.3%) | 1 (3.8%) | 0 (0%) | ||
| Neuroendocrine | 1 (1.3%) | 0 (0%) | 1 (2%) | ||
| Perioperative chemotherapy | No | 52 (67.5%) | 16 (61.5%) | 36 (70.6%) | 0.67 |
| Neoadjuvant | 12 (15.6%) | 5 (19.2%) | 7 (13.7%) | ||
| Adjuvant | 13 (16.9%) | 5 (19.2%) | 8 (15.7%) | ||
| Liver metastases | No | 61 (79.2%) | 22 (84.6%) | 39 (76.5%) | 0.7 |
| Yes | 15 (19.5%) | 4 (15.4%) | 11 (21.6%) | ||
| Not available | 1 (1.3%) | 0 (0.0%) | 1 (2.0%) | ||
| Bone metastases | No | 46 (59.7%) | 15 (57.7%) | 31 (60.8%) | 0.91 |
| Yes | 30 (39.0%) | 11 (42.3%) | 19 (37.3%) | ||
| Not available | 1 (1.3%) | 0 (0.0%) | 1 (2.0%) | ||
| Lymph node only metastases | Yes | 15 (19.5%) | 5 (19.2%) | 10 (19.6%) | 1 |
| Visceral metastases | Yes | 60 (77.9%) | 21 (80.8%) | 39 (76.5%) | 1 |
| Not available | 1 (1.3%) | 0 (0.0%) | 1 (2.0%) | ||
| First-line treatment for mUC | Cisplatin-based | 33 (42.8%) | 11 (42.3%) | 22 (44.0%) | |
| Checkpoint inhibitors | 23 (29.9%) | 5 (19.2%) | 18 (36.0%) | ||
| Carboplatin-based | 8 (10.4%) | 2 (7.7%) | 6 (12.0%) | ||
| FGFR inhibitor | 5 (6.5%) | 5 (19.2%) | 0 (0.0%) | ||
| Vinflunine | 3 (3.9%) | 1 (3.8%) | 2 (4.0%) | ||
| Best supportive care | 2 (2.6%) | 2 (7.7%) | 0 (0.0%) | ||
| Paclitaxel | 1 (1.3%) | 0 (0.0%) | 1 (2.0%) | ||
| Surgery | 1 (1.3%) | 0 (0.0%) | 1 (2.0%) | ||
| Not available | 1 (1.3%) | (0%) | 1 (2.0%) |